Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

Completed

Conditions: Allergic Rhinitis

Interventions: Other: Observational

Registration Number: NCT05146206

Lead Sponsor: Community and Patient Preference Research Pty Ltd

Brief Summary: The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

Detailed Description: The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. Participants will complete an online survey involving a Best-Worst scaling (BWS) task to determine satisfaction and importance index for sensory attributes.

The suggested treatment attributes are informed by a range of previous studies, including those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own work in developing indices for importance and satisfaction of treatment attributes using BWS.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 426

Inclusion Criteria

Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:

Patients above 18 years old
Fluent in English
Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment
Willing and able to provide consent to participate

Exclusion Criteria

Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition)
Are employed by a pharmaceutical company (to avoid conflict of interest)
Are employed by a vaccine company (to avoid conflict of interest)
Do not have access to the internet (to ensure validity of the data)
Are unable to read and understand English (to ensure validity of the data)

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients on DYMISTA	Observational	Patients who are currently using DYMISTA nasal spray.
Patients on RYALTRIS	Observational	Patients who are currently using RYALTRIS nasal spray.

Primary Outcome Measures

Name	Time	Method
Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score)	Cross-sectional - through study completion, an average of 3 months	The primary study endpoint is the overall index score from the Best Worst Scaling exercise, to reflect satisfaction and importance of treatment attributes of the RYALTRIS® and DYMISTA® nasal spray. Index scores from the Best Worst Scaling exercise range from 0 to 100, with higher scores indicating higher satisfaction of treatment attributes.

Secondary Outcome Measures

Name	Time	Method
Rescaled Scores From Best-Worst Scaling Task	Cross-sectional - through study completion, an average of 3 months	Secondary study endpoints were the rescaled Best Worst Scaling domain scores from the Best Worst Scaling exercise (i.e., scores for each of the domains on satisfaction and importance). Rescaled Best-Worst Scaling domain scores range from 0 to 10 and represent the satisfaction and importance of each domain. Higher satisfaction rescaled scores indicate higher satisfaction on a treatment attribute. Higher importance rescaled scores indicate higher importance of the treatment attribute. Higher rescaled satisfaction and importance scores suggest a better outcome since participants are satisfied and more likely to adhere to their current treatment.